Ipragliflozin

DB11698InvestigationalSmall molecule

Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

Chemical structure of Ipragliflozin
Mechanism
Curator reviewed
Formula / weight
C21H21FO5S · 404.45 g/mol (avg)

Resolves to

Compound
UNII3N2N8OOR7XCAS761423-87-4ChEMBLCHEMBL2018096ChEBI134724PubChem10453870
Clinical / RWD
ATCA10BK05
Structure
InChIKeyAHFWIQIYAXSLBA-RQXATKFSSA-NSMILESOC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1
Targets
P31639SLC5A2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
609Drug interactionsStructured to mechanism, not free text
Sign in
20Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 9 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ipragliflozin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In